Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
A recession-friendly withdrawal plan prioritizes sustainability. Find rules and examples to keep your withdrawals aligned with market conditions.
21,577 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Hyperscale AI demand is tightening packaging capacity. Intel's EMIB-T presents a potential workaround as chip packagi...
Bold moves in the logistics space are reshaping Amazon’s growth story. This article breaks down what the latest annou...
As markets swing in 2026, investors revisit Ted Turner's risk-taking era, drawing lessons on diversification, leverag...
A china-focused fund cuts million from Mattel in a first-quarter move. This article explains why such moves happen, w...
Eli Lilly dominates the GLP-1 space, but competition is heating up from outside and inside its own lineup. This guide...
Under Armour CEO Kevin Plank reiterates a belief in targeted micromanagement to speed product cycles in a volatile re...
A strategic shift in how the government engages with industry is triggering a market rethink. The administration is t...
Arm Holdings has surged 104% year-to-date, with the AI pivot and AGI CPU driving demand. Smart money sits near a spec...
A notable fund sold a sizable stake in a leading pet-food company, triggering questions about motive, timing, and imp...
Five large-cap dividend payers have topped the list of dependable growers, lifting their payouts by double digits for...
Choosing when to claim Social Security is tough for couples. This guide breaks down the reasons to delay, the tradeof...